Xynomic Pharmaceuticals, a US-China clinical-stage oncology company, will be merged into Bison Capital Acquisition in a reverse merger that values Xynomic at $450 million. Initially, Xynomic shareholders will receive $350 million in Bison shares, with another $100 million available if the company meets specified milestones. The company said a NASDAQ listing will improve its access to capital. In its two-year history, Xynomic has in-licensed two novel oral small-molecule cancer treatment candidates. Bison, a special purpose vehicle, will change its name to Xynomic Pharmaceuticals Holding. More details....
Stock Symbol: (NSDQ: BCAC)
Share this with colleagues: